Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?

详细信息    查看全文

• 作者：Azam-Sadat Mousavi (1)
  Moradi Marjan Mazhari (1)
  Mitra Modares Guilani (1)
  Fatemeh Ghaemmaghami (1)
  Nadereh Behtash (1)
  Setareh Akhavan (1)
  
• 刊名：World Journal of Surgical Oncology
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：8
• 期：1
• 全文大小：228KB
• 参考文献：1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. / CA Cancer J Clin 1999, 49: 8鈥?1. CrossRef
  2. Scully RE, Young RH, Clement PB: Tumors of ovary, maldeveloped gonads, fallopian, tube, and broad ligament. In / Atlas of tumor pathology, fascicle 23 3rd series. Washington, DC: Armed Forces Institute of pathology; 1998:1鈥?68.
  3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. / CA Cancer J clin 2003, 53: 5鈥?6. CrossRef
  4. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage3 epithelial ovarian cancer: a gynecologic oncology group study. / Gynecol Oncol 1992, 47: 159鈥?6. CrossRef
  5. Hoskins WJ, McGurie WP, Brady MF, Homseley HD, Creaseman WT, Berman M, Ball H, Berek JS: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. / Am J Obstet Gynecol 1994, 170: 974鈥?0.
  6. Hoskins WJ: Epithelial ovarian carcinoma: principles of primary surgery. / Gynecol Oncol 1994, 55: s91鈥?6. CrossRef
  7. Bristow BE, Tomacruz BS, Armstrong DK, Elmontz EL: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta analysis. / J Clin Oncol 2002, 20: 1248鈥?259. CrossRef
  8. Vergote I, DeWever I, Tjalma W, Gramberen M, Decloedt J, Dam P: Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 258 patients. / Gynecol Oncol 1998, 71: 431鈥?. CrossRef
  9. Eisenkop SM, Friedman Rl, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective studt. / Gynecol Oncol 1998, 69: 103鈥?. CrossRef
  10. Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD: Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. / Obstet Gynecol 1986, 67: 783鈥?. CrossRef
  11. Burg ME, van Lent M, Buyse M, Kobierska A, colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. / N Engl J Med 1995, 332: 629鈥?34. CrossRef
  12. Onnis A, Marchetti M, Padovan P, Castellan L: Neoadjuvant chemotherapy in advanced ovarian cancer. / Eur J Gynaecol Oncol 1996, 17: 393鈥?.
  13. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP: Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. / Gynecol Oncol 1999, 72: 93鈥?9. CrossRef
  14. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, Lhomme C, Scherer C, Tigaud JD, Benchaib M, Fourme E, Castaigene D, Querleu D, Dargent D: Neoadjuvant chemotherapy for unresectable ovarian carcinoma. A French multicenter study. / Cancer 2001, 91: 2329鈥?4. CrossRef
  15. Eisenkop SM, Spirtos NM: What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologist treating advanced epithelial ovarian cancer? / Gynecol Oncol 2001, 82: 489鈥?7. CrossRef
  16. Nelson BE, Rosenfeld AT, Schwardz PE: Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. / J Clin Oncol 1993, 11: 166鈥?2.
  17. Barlow M, Pazybylkski M, Schilder Jm: The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. / Int J Gynecol Cancer 2006, 16: 495鈥?00. CrossRef
  18. Memarzadeh, Lee SB, Berek JS, Farias-Eisner R: Ca-125 levels are a weak predictor of optimally cytoreductive surgery in patients with advance epithelial ovarian cancer. / Int J Gynecol Cancer 2003, 13: 120鈥?24. CrossRef
  19. Martinez-Said H, Rincon DG, Montes De Oca MM, Ruiz GC, Ponce JLA, Lopez-Graniel CM: Predictive factors for irresectibility in advanced ovarian cancer. / Int J Gynecol Cancer 2004, 14: 423鈥?0. CrossRef
  20. Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A: Factors associated with cytoreducibility among women with ovarian carcinoma. / Gynecol Oncol 2004, 95: 377鈥?3. CrossRef
  21. Chan YM, Ng TY, Ngan HYS, Wong LC: Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. / Gynecol Oncol 2002, 88: 9鈥?6. CrossRef
  22. Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut Hv, Mancuso S, Scambia G: Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage3c ovarian cancer patients. / Oncology 2003, 65: 316鈥?2. CrossRef
  23. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, Lhomm茅 C, Duvillard P, Castaigne D: Results of interval debulking surgery compared with primary debulking surgery in advanced stage epithelial ovarian cancer. / J Am Coll Surg 2003, 197: 955鈥?3. CrossRef
  24. Lu KF, Kose MF, Boran N, Caliskan E, Tulunay G: Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. / Int J Gynecol Cancer 2001, 11: 466鈥?0. CrossRef
  25. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, Weaver JP, Gabbay M, Ngo M, Lentz S, Cass I, Li AJ, Karlan BY, Holschneider CH: Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. / J Clin Oncol 2007, 25 (4) : 384鈥?. CrossRef
  
• 作者单位：Azam-Sadat Mousavi (1)
  Moradi Marjan Mazhari (1)
  Mitra Modares Guilani (1)
  Fatemeh Ghaemmaghami (1)
  Nadereh Behtash (1)
  Setareh Akhavan (1)
  
  1. Department of Gynecology Oncology, vali-e-asr hospital, Tehran University of Medical Sciences, Keshavarz Blvd, 1419733141, Tehran, Iran
  

文摘

Introduction Prediction of optimal cytoreduction in patients with advanced epithelial ovarian caner preoperatively. Methods Patients with advanced epithelial ovarian cancer who underwent surgery for the first time from Jan. to June 2008 at gynecologic oncology ward of TUMS (Tehran University of Medical Sciences) were eligible for this study. The possibility of predicting primary optimal cytoreduction considering multiple variables was evaluated. Variables were peritoneal carcinomatosis, serum CA125, ascites, pleural effusion, physical status and imaging findings. Univariate comparisons of patients underwent suboptimal cytoreduction carried out using Fisher's exact test for each of the potential predictors. The wilcoxon rank sum test was used to compare variables between patients with optimal versus suboptimal cytoreduction. Results 41 patients met study inclusion criteria. Statistically significant association was noted between peritoneal carcinomatosis and suboptimal cytoreduction. There were no statistically significant differences between physical status, pleural effusion, imaging findings, serum CA125 and ascites of individuals with optimal cytoreduction compared to those with suboptimal cytoreduction. Conclusions Because of small populations in our study the results are not reproducible in alternate populations. Only the patient who is most unlikely to undergo optimal cytoreduction should be offered neoadjuvant chemotherapy, unless her medical condition renders her unsuitable for primary surgery.